Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

International Journal of Clinical Oncology

Volumn 21, Issue 3, 2016, Pages 491-497

  Yahata, Hideaki ^a   Kobayashi, Hiroaki ^b   Sonoda, Kenzo ^a   Shimokawa, Mototsugu ^c   Ohgami, Tatsuhiro ^d   Saito, Toshiaki ^c   Ogawa, Shinji ^e   Sakai, Kunihiro ^f   Ichinoe, Akimasa ^g   Ueoka, Yousuke ^h   Hasuo, Yasuyuki ⁱ   Nishida, Makoto ^j   Masuda, Satohiro ^a   Kato, Kiyoko ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^e Kyushu Women's Junior College   (Japan)

^f Saiseikai Fukuoka Hospital   (Japan)

^g KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^h HAMANOMACHI HOSPITAL   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^j FUKUOKA RED CROSS HOSPITAL   (Japan)

more..

Author keywords

Aprepitant; CINV; Gynecologic cancer; Hypersensitivity reaction; MEC regimen

Indexed keywords

APREPITANT; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PACLITAXEL; PLACEBO; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; JAPANESE (PEOPLE); LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERUS CANCER; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG HYPERSENSITIVITY; GENITAL NEOPLASMS, FEMALE; MIDDLE AGED; NAUSEA; REMISSION; VOMITING; YOUNG ADULT;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; MORPHOLINES; NAUSEA; PACLITAXEL; REMISSION INDUCTION; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING; YOUNG ADULT;

EID: 84949555638     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0928-y     Document Type: Article

References (22)

1. Weiderpas E, Sandin S, Inoue M et al (2012) Risk factors for epithelial ovarian cancer in Japan: results from the Japan public health center-based prospective study cohort. Int J Oncol 40(1):21–30
2. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947
3. Roila F, Fatigoni S (2006) New antiemetic drugs. Ann Oncol 17[Suppl 2]:ii96–ii100
4. Japan Society of Clinical Oncology (2014) Guidelines for appropriate use of antiemetic drugs, version 1.2. Kanehara, Tokyo
5. Ettinger DS, Armstrong DK, Barbour S et al (2012) Antiemesis. J Natl Compr Cancer Netw 10:456–485
6. Campos D, Pereira JR, Reinhardt RR et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19(6):1759–1767
7. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119
8. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting. Results from a randomized, double blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098
9. Takahashi T, Hoshi E, Takagi M et al (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101(11):2455–2461
10. du Bois A, Luck HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329
11. Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682–1691
12. Furukawa N, Akasaka J, Shigemitsu A et al (2014) Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin. Gynecol Oncol 289(4):859–864
13. Itoh Y, Sendo T, Hirakawa T et al (2004) Sensory nerve peptides rather than mast cell histamine are involved in paclitaxel hypersensitivity reactions. Am J Resp Crit Care Med 169:113–119
14. Itoh Y, Sendo T, Hirakawa T et al (2004) Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology 46:888–894
15. Yahata H, Saito M, Sendo T et al (2006) Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int J Cancer 118(10):2636–2638
16. Bernaldo L, Rapoport BL, Jordan K et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431
17. Wiernik PH, Schwartz EL, Strauman JJ et al (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486–2493
18. Markman M, Kennedy A, Webster K et al (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 125:427–429
19. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21[Suppl 5]:v232–v243
20. Basch E, Prestrud AA, Hesketh PJ et al. (2012) Antiemetic use in oncology: updated guideline recommendations from ASCO. Am Soc Clin Oncol Educ Book 53:2–540
21. Roscoe JA, Heckler CE, Morrow GR et al (2012) Prevention of delayed nausea: a University of Rochester cancer center community clinical oncology program study of patients receiving chemotherapy. J Clin Oncol 30(27):3389–3395
22. Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20(5):855–865